{"id":97,"date":"2023-12-21T10:00:00","date_gmt":"2023-12-21T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=97"},"modified":"2025-09-01T00:58:59","modified_gmt":"2025-09-01T00:58:59","slug":"china-bd-deal-2023-hansoh-and-gsk-enters-a-1-71-billion-usd-license-on-b7-h3-adc-hs-20093","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/97.html","title":{"rendered":"[China BD Deal 2023] Hansoh and GSK enters a 1.71 billion USD license on B7-H3 ADC HS-20093"},"content":{"rendered":"\n<p>Announced Date: 2023-12-20 (December 20, 2023)<\/p>\n\n\n\n<p>Asset Name: HS-20093<\/p>\n\n\n\n<p>Licensor: Hansoh Pharma\u00a0 (Hansoh) (China)<\/p>\n\n\n\n<p>Licensee (Buyer): GSK plc\u00a0\uff08UK\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Antibody-drug conjugate (ADC)\u00a0<\/p>\n\n\n\n<p>Asset Target: B7-H3\u00a0\uff0ctopoisomerase inhibitor (TOPOi)\u00a0 payload<\/p>\n\n\n\n<p>Potential indication\uff1aLung cancer, solid tumour<\/p>\n\n\n\n<p>Current Stage: phase I and II trials in China<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>GSK will obtain exclusive worldwide rights (excluding China\u2019s mainland, Hong Kong, Macau, and Taiwan) to progress clinical development and commercialisation of HS-20093.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of\u00a0 $185 million;<\/p>\n\n\n\n<p>Milestone payments up to $1.525 billion;<\/p>\n\n\n\n<p>Total up to  $1.71 billion.<\/p>\n\n\n\n<p>Additional royalties based on net sales in the licensed territories.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>GSK enters exclusive license agreement with Hansoh for HS-20093<\/p>\n\n\n\n<p><a href=\"https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093\/\">https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093\/<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-12-20 (December 20, 2023) Asset Name: HS-20093 Licensor: Hansoh Pharma\u00a0 (Hansoh) (China) Licensee (Buyer): &hellip; <a title=\"[China BD Deal 2023] Hansoh and GSK enters a 1.71 billion USD license on B7-H3 ADC HS-20093\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/97.html\"><span class=\"screen-reader-text\">[China BD Deal 2023] Hansoh and GSK enters a 1.71 billion USD license on B7-H3 ADC HS-20093<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-97","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/97","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=97"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/97\/revisions"}],"predecessor-version":[{"id":98,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/97\/revisions\/98"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=97"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=97"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=97"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}